These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3457966)

  • 1. [Clinical evaluation of a cancer antigen, CA 15-3, associated with breast cancer. (I) Modification of its method and reference values].
    Sakurabayashi I; Kawai T; Kawaguchi R; Yonezawa M
    Rinsho Byori; 1986 Jan; 34(1):53-8. PubMed ID: 3457966
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
    Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
    Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
    [No Abstract]   [Full Text] [Related]  

  • 3. [A new carbohydrate antigen CA 19-9 associated with malignancies of digestive system. I. Modification of its method and reference values].
    Sakurabayashi I; Kawai T; Yamanaka T; Kimura K; Yagisawa K; Igarashi S; Yonezawa M; Ioku A
    Rinsho Byori; 1984 May; 32(5):539-45. PubMed ID: 6592377
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
    Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
    Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of a tumor-associated antigen CA 15-3 in the sera of patients with breast cancer].
    Ogawa T; Izuo M; Morita H; Ishida T; Iino Y; Hoshino K; Yokoe T; Suzuki H; Murata S; Matsuzaki S
    Gan No Rinsho; 1986 Jan; 32(1):27-32. PubMed ID: 3456454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tissue polypeptide antigen in breast cancer].
    Nomizu T; Watanabe I; Endo S
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2287-95. PubMed ID: 6085339
    [No Abstract]   [Full Text] [Related]  

  • 8. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
    Vindimian M; Lafitte JJ; Wattre P
    Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic studies and the reference values of cancer associated antigen CA-50].
    Yoshioka H; Shitara M; Sakurabayashi I; Kawai T; Suzuki M
    Rinsho Byori; 1988 Feb; 36(2):171-6. PubMed ID: 3288785
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
    Forti E; Wolf D; Melia M
    Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
    [No Abstract]   [Full Text] [Related]  

  • 11. [Serum CA-125 level in patients with gynecologic tumors].
    Abe Y; Ueda G; Yamasaki M; Inoue M; Hiramatsu K; Inoue Y; Saito J; Nishino T
    Rinsho Byori; 1984 Dec; 32(12):1350-4. PubMed ID: 6597876
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer).
    Ruibal A; Encabo G; Genollá J; Guarga A; Urrutia A; Colomer R
    Bull Cancer; 1986; 73(1):94-5. PubMed ID: 3465383
    [No Abstract]   [Full Text] [Related]  

  • 14. [The place of tumor markers in breast and gynecologic neoplasms].
    Gosselin P; Cazin JL; Demaille MC; Sulman C
    Rev Fr Gynecol Obstet; 1988; 83(7-9):535-40. PubMed ID: 3057569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of serum CA-50 measurement in breast diseases --relation to the progress of breast cancer].
    Shiga T; Kawauchi A; Kamiya K; Ishii J; Uzawa R; Gomi K
    Rinsho Byori; 1986 Nov; 34(11):1339-45. PubMed ID: 3469447
    [No Abstract]   [Full Text] [Related]  

  • 16. [Significance of the determination of serum CA19.9 in patients with tumor or non-tumor pancreatopathies].
    Encabo G; Ruibal A; Gefaell R; Martínez Miralles E; Salgado A; Fernández Llamazares J
    Med Clin (Barc); 1984 Mar; 82(12):560-1. PubMed ID: 6588282
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fundamental studies and the reference values of cancer associated antigen TAG-72 (CA72-4)].
    Shitara M; Yoshioka H; Sakurabayashi I; Kawai T; Suzuki M
    Rinsho Byori; 1988 Oct; 36(10):1177-81. PubMed ID: 3246730
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
    Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
    Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of a cancer antigen CA 125 associated with ovarian cancer. II. Serum CA 125 levels in normal pregnancy].
    Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Jan; 33(1):73-6. PubMed ID: 3857365
    [No Abstract]   [Full Text] [Related]  

  • 20. Value of CA 15:3 in the follow-up of breast cancer patients.
    Pons-Anicet DM; Krebs BP; Mira R; Namer M
    Br J Cancer; 1987 May; 55(5):567-9. PubMed ID: 3475109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.